Lenvika 10 mg (Capsule)
Unit Price: ৳ 1,300.00 (3 x 10: ৳ 39,000.00)
Strip Price: ৳ 13,000.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Lenvatinib mesylate |
| Company | Genvio pharma ltd |
| Also available as |
Indications
- Locally recurrent or metastatic differentiated thyroid cancer treatment
- Renal cell carcinoma treatment
- Hepatocellular carcinoma treatment
- Endometrial carcinoma treatment
Pharmacology
- Kinase inhibitor
- Inhibition of VEGF receptors
- Inhibition of FGF receptors
- Inhibition of PDGFR, KIT, and RET
Absorption
- Time to peak plasma concentration (Tmax) 1-4 hours post-dose
- Effect of high-fat meal on absorption
Distribution
- In vitro binding to human plasma proteins 98%-99%
- Blood-to-plasma concentration ratio
Metabolism
- Main metabolic pathways: enzymatic and non-enzymatic processes
- Excretion in feces and urine
Elimination
- Terminal elimination half-life approximately 28 hours
Dosage
- Dose reduction for renal or hepatic impairment
- Administration once daily with or without food
- Recommended dosages for differentiated thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, endometrial carcinoma
Administration
- Swallowing whole capsules or dissolving in liquid
- Instructions for dissolving in liquid
Interaction
- Prolongation of QT interval
- Avoid coadministration with drugs prolonging the QT interval
Contraindications
- Known hypersensitivity
Side Effects
- Hypertension
- Cardiac dysfunction
- Arterial thromboembolic events
- Hepatotoxicity
- Renal failure and impairment
- Proteinuria
- Diarrhea
- Fistula formation and gastrointestinal perforation
- QT Interval Prolongation
- Hypocalcemia
- Reversible posterior leukoencephalopathy syndrome
- Hemorrhagic events
- Impairment of thyroid stimulating hormone suppression/thyroid dysfunction
- Wound healing complications
Pregnancy & Lactation
- Potential embryo-fetal harm
- Need for effective contraception
- Unknown presence in human milk
- Advice to discontinue breastfeeding
Precautions & Warnings
- Hypertension monitoring and control
- Cardiac dysfunction monitoring
- Arterial thromboembolic events management
- Hepatotoxicity monitoring
- Renal failure or impairment management
- Proteinuria monitoring
- Diarrhea management
- Fistula formation and gastrointestinal perforation management
- QT Interval Prolongation monitoring and correction
- Hypocalcemia management
- Reversible posterior leukoencephalopathy syndrome management
- Hemorrhagic events risk consideration
- Impairment of thyroid stimulating hormone suppression/thyroid dysfunction monitoring
- Wound healing complications management
Use in Special Populations
- Dosage modifications for severe renal impairment
- Dosage modifications for severe hepatic impairment
- No established safety and effectiveness in pediatric patients
Overdose Effects
- High plasma protein binding
- Not expected to be dialyzable
- Reported death from multiorgan dysfunction
Storage Conditions
- Store below 30°C
- Dry place
- Protection from light
- Keep out of the reach of children